Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: David Lewis, Steven Kanner, Stanley Crooke, David Suhy


Arrowhead Research has named David Lewis as its new chief scientific officer.

Lewis most recently served as site head for the company's Madiscon, Wis., research and development facility, which Arrowhead acquired from Roche in 2011. Before that, he held various positions with Mirus Bio, which was acquired by Roche in 2007.

Arrowhead also said that Steven Kanner has joined the company as vice president of biology, taking over Lewis' former role. Previously, Kanner was vice president of discovery biology at Astek Pharmaceuticals.

Isis Pharmaceuticals announced that CEO and Chairman Stanley Crooke has been awarded the 2013 Director of the Year Award for Companies in Transition from the non-profit Corporate Directors Forum.

Bio-Matrix Scientific Group said that David Suhy has joined the scientific advisory board of its subsidiary Regen BioPharma.

Suhy is currently the vice president of research and development at Tacere Therapeutics, a subsidiary of Benitec Biopharma currently developing an expressed RNAi-based treatment for hepatitis C.

Regen recently took a license to Benitec's technology for use in developing a cancer vaccine.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.